TUCSON, Ariz., Nov. 2, 2022 — Critical Path Institute (C-Path) and the Eisai Co., Ltd. (Eisai) today announced a joint collaboration to significantly promote data sharing and incorporate Lennox-Gastaut Syndrome (LGS) clinical trial data, into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading
Category Archives: AZBio News
Time to Apply for the Flinn Foundation Seed Grants to Promote Translational Research Program
Seed Grants application now open
In 2023, the Flinn Foundation Seed Grants to Promote Translational Research Program will fund up to 10 research teams affiliated with an Arizona university, research institution, or health-care system that are advancing new products or services to improve patient care.Continue reading
CashLabs LLC Acquires Beacon Biomedical Inc.
Phoenix, Ariz. (November 1, 2022) – CashLabs LLC, a Tucson Arizona based national laboratory platform, announced the acquisition of Beacon Biomedical, a Phoenix Arizona based CLIA accredited medical laboratory focused on the development and commercialization of early detection cancer screening tests.Continue reading
Crispr in diagnostics will be a revolution . . . eventually.
Two years ago this month, the Nobel Prize in Chemistry was awarded to two of the pioneers of the Crispr DNA-editing technique. Since then, it has displaced all other laboratory techniques for that purpose by virtue of its accuracy, simplicity, ease of use, and low cost.
How it works and why it was Nobel-worthyContinue reading
BIO and AZBio 2022 Reports Illustrate Bioindustry Impact
The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) today released new data on the bioscience industry in the United States. The report includes individual fact sheets for all 50 states, the District of Columbia and Puerto Rico, which can be found alongside the full report and interactive map at www.bio.org/jobs. AZBio uses this data and additional federally reported data to build its statewide progress report.
C-Path Appoints Neuropharmacology Expert as New Vice President – Rare and Orphan Disease Programs
Dr. Collin Hovinga will lead two public-private partnerships at C-Path — the Rare Disease Cures Accelerator Data and Analytics Platform (RDCA-DAP®) and the Critical Path for Rare Neurodegenerative Diseases (CP-RND).Continue reading
UArizona researchers develop ‘Goldilocks drug’ to treat triple-negative breast cancer
University of Arizona researchers have been working for decades to develop a drug that so specifically targets a deadly kind of breast cancer that there are little to no toxic side effects.Continue reading
NeoLight acquires first-of-its-kind musical pacifier technology for premature babies
SCOTTSDALE, Ariz., Oct. 25, 2022 /PRNewswire/ — NeoLight has signed an agreement to acquire the Pacifier Activated Lullaby (PAL®) System by Powers Medical Inc., a US-based medical technology company that focuses on musical therapy in the newborn baby market. This acquisition strengthens the NeoLight neonatal portfolio by introducing a solution for two growing concerns in newborn care; Non-nutritive sucking (NNS) and Neonatal Abstinence Syndrome (drug-addicted babies).Continue reading
Aesthetics Biomedical ® Inc. Announces FDA Clearance of Vivace Ultra™, The First-and-Only Personalized Radiofrequency (RF) Microneedling Technology
Revolutionizing treatments with unmatched precision and visionContinue reading